Aigen Investment Management, LP Geron Corp Transaction History

Aigen Investment Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$3.1 - $5.09 $91,508 - $150,251	29,519 New	29,519 $125,000
Q4 2023 Feb 09, 2024	SELL	$1.74 - $2.31 $193,291 - $256,610	-111,087 Reduced 83.43%	22,058 $46,000
Q3 2023 Nov 13, 2023	BUY	$2.11 - $3.28 $280,935 - $436,715	133,145 New	133,145 $282,000
Q3 2020 Nov 06, 2020	SELL	$1.59 - $2.19 $77,385 - $106,587	-48,670 Closed	0 $0
Q2 2020 Aug 10, 2020	BUY	$1.05 - $2.18 $51,103 - $106,100	48,670 New	48,670 $106,000

275

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.54B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

Stay updated on Aigen Investment Management, LP with notifications on news.